Abstract
Introduction WHO recommends a CD4 cell count before starting antiretroviral therapy (ART) to detect advanced HIV disease, and routine viral load (VL) testing following ART initiation to detect treatment failure. Donor support for CD4 testing has declined to prioritize access to VL monitoring. We examined trends in CD4 and VL testing among adults (≥15 years of age) starting ART in Southern Africa.
Methods We analysed data from 14 HIV treatment programs with over 300 clinics in Lesotho, Malawi, Mozambique, South Africa, Zambia and Zimbabwe in years 2005-2018. We examined the frequency of CD4 and VL testing, the percentage of adults with CD4 or VL tests, and among those having a test, the percentage starting ART with advanced HIV disease (CD4 count <200 cells/mm3) or failing to suppress viral replication (>1000 HIV-RNA copies/ml) after ART initiation. We used mixed effect logistic regression to assess time trends adjusted for age and sex.
Results Among 502,456 adults, the percentage with CD4 testing at ART initiation decreased from a high of 78.1% in 2008 to a low of 38.0% in 2017. The percentage starting with advanced HIV disease declined from 83.3% in 2005 to 23.5% in 2018. VL testing after starting ART varied; 61.0% of adults in South Africa and 10.7% in Malawi were tested but fewer than 2% were tested in the other four countries. The probability of having a CD4 cell count at ART start declined by 14% each year (odds ratio [OR] 0.86; 95% CI 0.86-0.86); the probability of advanced HIV disease declined by 20% per year (OR 0.80; 95% CI 0.80-0.81). The increase in VL testing after ART start was only modest (OR 1.06; 95% CI 1.05-1.06) and there was no evidence of a decrease in unsuppressed VL over time (OR 1.00; 95% CI 0.99-1.01).
Conclusions CD4 cell counting declined over time, including testing at the start of ART, despite the fact that many patients still initiated ART with advanced HIV disease. Without CD4 testing and expanded VL testing many patients with advanced HIV disease and treatment failure may go undetected, threatening the effectiveness of ART in sub-Saharan Africa.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding of the International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration was provided by 10 institutes, centers and programs of the US National Institutes of Health (NIH): the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) (https://www.niaid.nih.gov), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (https://www.nichd.nih.gov), the National Cancer Institute (NCI) (https://www.cancer.gov), the National Institute of Mental Health (NIMH) (https://www.nimh.nih.gov), the National Institute on Drug Abuse (NIDA) (https://www.drugabuse.gov), the National Heart, Lung, and Blood Institute (NHLBI) (https://www.nhlbi.nih.gov), the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (https://www.niaaa.nih.gov), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (https://www.niddk.nih.gov), the Fogarty International Center (FIC) (https://www.fic.nih.gov), and the National Library of Medicine (NLM) (https://www.nlm.nih.gov/) under Award Number U01AI069924. The research reported is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. National Institutes of Health. ME was supported by special project funding (Grant No. 174281) from the Swiss National Science Foundation (www.snf.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. National Institutes of Health or any governments or institutions mentioned above.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Complete data for this study cannot be posted in a supplemental file or a public repository because of legal and ethical restrictions. Disclosure of a person’s HIV status can be highly stigmatizing, and since reidentification of deidentified datasets may be possible when they are combined with publicly available datasets (see work of Dr. Latanya Sweeney), IeDEA promotes the signing of a Data Use Agreement before HIV clinical data can be released. To request data, readers may contact IeDEA for consideration and instructions by filling out the online form available at www.iedea.org/home/who-we-are and completing the application at www.iedea.org/wp-content/uploads/2017/05/IeDEA_Multiregional_Concept_Application_Form_August_2016.docx
